I'm really curious to see how their pharmaceutical/medical bets play out. This is a space that's very competitive with low R&D returns that seems outside YC's

I'm really curious to see how their pharmaceutical/medical bets play out. This is a space that's very competitive with low R&D returns that seems outside YC's previous domains. I think it will be rougher than they thought breaking into it, but if they can prove out a better funding model for pharmaceutical development that could have a huge impact.